156% rally in one day! Why this drugmaker stock witnessed such skyrocketing jump on Wall Street
Sellas Life Sciences shares surged 156% after its experimental leukemia vaccine, galinpepimut-S (GPS), significantly extended survival in a late-stage trial. The treatment reduced death risk by 41%, with median survival reaching 24 months. The com...

The drugmaker said that its study covering 126 patients found that its vaccine cut the risk of death by 41% compared to best available treatment.
After closing at $7.47 per share on Monday, Sellas Life Sciences surged to $19.15 per share on Tuesday on the Wall Street. The sharp gains added more than $2.38 billion to the company’s market capitalisation in just one day, pulling it up to $3.9 billion.
To put the explosive returns in context, an investor who bought 100 shares on Monday would see the total value of her holding surge to $1,915 from $747 just the day before, implying a return of $1,168 in just one day.
Also read | Nvidia shares jump 5% in after-hours as quarterly earnings beat estimates. Is the storm around Huang’s exit finally over?
Why did Sellas Life Sciences skyrocket?
Sellas Life Sciences said its vaccine called galinpepimut-S or GPS was tested on patients with acute myeloid leukemia (AML), who were in remission after cancer therapy but were unable to receive a bone marrow or stem-cell transplant. AML is a type of aggressive cancer of the blood and bone marrow. Patients whose disease often returns after treatment face limited care options currently.The drugmaker said that its study covering 126 patients found that its vaccine cut the risk of death by 41% compared to best available treatment. Patients treated with the vaccine lived for a median of 24 months, versus 14.7 months for those in the control group. The vaccine works by training the body's immune system to find and attack leftover leukemia cells that carry a protein called WT1.
For fragile patients "already battered by prior lines of intensive chemotherapy, delivering longer life without adding systemic toxicity would be nothing short of transformative," CEO Angelos Stergiou said during a conference call.
According to the American Cancer Society, around 22,720 people will likely be diagnosed with AML and around 11,500 are expected to die from the disease in 2026. AML accounts for 1 out of 3 leukemia in adults. Sellas meanwhile plans to meet with the US FDA to discuss an accelerated filing strategy, aiming to submit an approval application in the first half of 2027. The New York-based company said the vaccine was generally well tolerated and raised no new safety concerns.
Also read | Warren Buffett feels this compounds better than any stock he ever bought as legendary investor donates $5.5 billion to charities
The trial result was "incredibly clinically meaningful", Reuters quoted Alliance Global Partners analyst James Molloy. "We believe GPS should receive an expedited approval in 2027 as a monotherapy... and that it could see significant off-label usage earlier in the treatment paradigm as well,” he added.
Disclaimer: This article has been written by Debaroti Adhikary, who is not a SEBI-registered Research Analyst or an Investment Adviser. Debaroti Adhikary and his/her ‘relative(s)’ (as defined under Section 2(77) of the Companies Act, 2013) do not hold any financial interest in the companies mentioned in this article as of the date of publication. The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here.
Download ET Markets APP